

# NORTH AMERICAN DIETARY SUPPLEMENTS

Prepared by:

CPL Business Consultants

Innovation Centre, Milton Park, Abingdon, Oxfordshire, OX14 4RY

Tel: +44 1865 257 057, [info@cplconsult.com](mailto:info@cplconsult.com), [www.cplconsult.com](http://www.cplconsult.com)

Dr Robert Harwood  
Ms Megha Chugh MSc  
Dr Esther Hunter  
Dr Steve Lisansky

STRATEGIES TO GROW YOUR BUSINESS

TABLE OF CONTENTS

OBJECTIVE AND BACKGROUND..... 8
METHOD ..... 9
PRINCIPAL FINDINGS..... 10
MARKETS..... 10
VALUE CHAIN..... 10
SALES CHANNELS ..... 11
COMPETITION..... 12
PLAYERS ..... 12
Retail channel..... 12
Direct-marketing channel..... 13
Practitioner channel..... 13
PRODUCTS..... 14
US..... 14
Canada ..... 16
Mexico ..... 17
VIEWS OF CONTACTS ..... 18
Cholesterol-Lowering Market ..... 18
Phytosterols ..... 18
Marketing ..... 19
Regulations and claims..... 20
R&D ..... 22
Views on Product A ..... 22
CASE STUDIES..... 23
Product A case..... 23
Product B case..... 26
REGULATIONS..... 27
US..... 27
Canada ..... 27
Mexico ..... 27
NEWS ..... 28
PHARMACEUTICALS ..... 29
CONCLUSIONS ..... 34
MARKETS..... 34
SALES CHANNELS ..... 34
COMPETITION..... 34
MARKETING AND PROMOTION ..... 35
PRODUCTS..... 35
VIEWS OF CONTACTS ..... 36
CASE STUDIES..... 38
Product A case..... 38
Product B case..... 39
REGULATIONS..... 39
NEWS ..... 39
PHARMACEUTICALS ..... 40
SOME SUMMARY THOUGHTS ON THE MARKET..... 43
RECOMMENDATIONS..... 44
KEY SUCCESS FACTORS ..... 45
SWOT FOR CLIENT IN DIETARY SUPPLEMENTS ..... 46
SUMMARY OF SPREADSHEET RESULTS..... 47

<b>MARKETS .....</b>	<b>51</b>
SEGMENTATION .....	51
<i>Vitamins</i> .....	51
<i>Minerals</i> .....	51
<i>Herbs &amp; Botanicals</i> .....	51
<i>Specialty Supplements</i> .....	51
<i>Meal Supplements</i> .....	51
<i>Sports Nutrition</i> .....	51
SALES CHANNELS .....	51
<i>Retail Channels</i> .....	51
<i>Direct Channels</i> .....	52
SIZE IN VOLUME AND VALUE.....	52
<i>Heart Health Supplements</i> .....	56
<b>THE SUPPLEMENTS VALUE CHAIN.....</b>	<b>58</b>
SUPPLY CHAIN - THE SUPPLEMENTS INDUSTRY .....	58
VALUE CHAIN – US NUTRITION INDUSTRY .....	59
SUPPLY CHAIN – US NUTRITION INDUSTRY.....	61
SALES CHANNELS .....	67
<i>Retail Channels</i> .....	68
<i>Non-Retail Channels</i> .....	71
<b>PLAYERS.....</b>	<b>75</b>
SUMMARY.....	75
<i>Direct marketing channel</i> .....	75
<i>Practitioner Sales channel</i> .....	75
RETAIL SUPPLEMENT COMPANIES .....	76
<i>3 companies</i> .....	77
DIRECT SELLING SUPPLEMENT COMPANIES.....	82
<i>9 companies</i> .....	82
PRACTITIONER CHANNEL SALES IN US.....	100
<i>10 companies</i> .....	101
<b>CHOLESTEROL-LOWERING AGENTS.....</b>	<b>116</b>
PRESCRIPTION DRUGS .....	116
<i>Statins (also known as HMG CoA reductase inhibitors)</i> .....	118
<i>Bile Acid Sequestrants (or also called Resins)</i> .....	118
<i>Nicotinic Acid</i> .....	118
<i>Fibrates</i> .....	119
<i>Ezetimibe</i> .....	119
SUPPLEMENTS.....	119
<i>Artichoke leaf extract</i> .....	121
<i>Fenugreek</i> .....	121
<i>Fibre</i> .....	122
<i>Fish oil</i> .....	122
<i>Garlic</i> .....	123
<i>Ginseng</i> .....	123
<i>Guggul</i> .....	124
<i>Niacin</i> .....	124
<i>Red yeast rice</i> .....	125
<i>Soy protein</i> .....	125
PHYTOSTEROL/STANOL SUPPLIERS .....	126
<b>PRODUCTS.....</b>	<b>128</b>
INTRODUCTION .....	128
US PRODUCTS.....	128
<i>48 products</i> .....	136
CANADIAN PLAYERS & PRODUCTS .....	191
MEXICO .....	194
<i>Players</i> .....	194

<i>Sales Channels</i> .....	194
<b>REGULATIONS</b> .....	<b>197</b>
IADSA FRAMEWORK.....	197
US.....	197
<i>Background</i> .....	197
<i>Labelling of Supplements Containing Sterols and Stanols</i> .....	199
CANADA.....	203
<i>Scope of the Natural Health Products Regulations</i> .....	204
<i>Main Components of the Natural Health Products Regulations</i> .....	205
<i>Guidance Documents</i> .....	207
<i>List of Included Substances</i> .....	210
<i>List of Excluded Substances</i> .....	210
<i>Dosage Form and Bulk Herbs</i> .....	211
<i>Hybrid Products</i> .....	211
<i>Activities Covered by the Natural Health Products Regulations</i> .....	211
MEXICO .....	215
<i>Background</i> .....	215
<i>Import Permits</i> .....	216
<b>CONTACT REPORTS</b> .....	<b>217</b>
OVERVIEW .....	217
<i>Market size and growth</i> .....	217
<i>Marketing</i> .....	218
<i>Regulations and claims</i> .....	220
<i>Case Study – Product A</i> .....	222
CONTACT REPORTS .....	224
<i>29 contacts</i> .....	224
<b>CASE STUDIES</b> .....	<b>249</b>
COMPANY X.....	249
<i>Overview</i> .....	249
<i>The Product A Story</i> .....	251
COMPANY Y.....	259
<i>Innovation, Protection, Communication</i> .....	260
<i>Product Quality</i> .....	261
COMPANY Z.....	261
<i>Marketing</i> .....	261
<i>Opportunities for application</i> .....	262
<i>Consumer Awareness</i> .....	262
<i>Role of Science</i> .....	262
<i>Implication of Market data</i> .....	262
<b>NEWS ARTICLES</b> .....	<b>264</b>
SUMMARY .....	264
<i>Market</i> .....	264
<i>Recent Scientific Studies</i> .....	265
<i>Statins – a potential OTC threat</i> .....	265
<i>Competition</i> .....	266
<i>Consumer education &amp; awareness</i> .....	266
<i>New product formulations</i> .....	267
<i>Brand recognition</i> .....	267
PRESS ARTICLES .....	267
<i>25 articles</i> .....	267
<b>PATENTS</b> .....	<b>303</b>
WORLD PATENTS .....	303
<i>4 patents</i> .....	303
US PATENTS .....	304
<i>1 patent</i> .....	305

<b>FOCUS ON THE UNDERSTANDING OF CORONARY HEART DISEASE.....</b>	<b>306</b>
INTRODUCTION .....	306
HOW CORONARY HEART DISEASE ORIGINATES.....	306
INCIDENCE OF CHD .....	307
CAUSES OF CHD .....	309
DIAGNOSIS OF CHD.....	314
<i>Signs &amp; Symptoms</i> .....	314
<i>Diagnostic Techniques</i> .....	315
TREATMENTS FOR CHD .....	318
CLINICAL TRIALS .....	321
<b>FOCUS ON CHOLESTEROL AND CHOLESTEROL-LOWERING DRUGS.....</b>	<b>328</b>
HYPERCHOLESTEROLEMIA AND CORONARY HEART DISEASE (CHD) .....	328
<i>Cholesterol Guidelines</i> .....	330
<i>Cholesterol in the Population</i> .....	331
<i>High blood pressure</i> .....	331
<i>Cholesterol Management</i> .....	332
CLINICAL TRIALS OF CHOLESTEROL-LOWERING DRUGS .....	343
<b>SUMMARY .....</b>	<b>346</b>
<b>NEWS ON PHARMACEUTICALS.....</b>	<b>347</b>
OVERVIEW OF MOST RECENT NEWS .....	347
NEWS ARTICLES .....	351
<i>55 articles</i> .....	351
EXAMPLES OF RESEARCH & PATENTS.....	446
<i>4 items</i> .....	446
<b>APPENDIX 1 – FTC GUIDANCE ON ADVERTISING DIETARY SUPPLEMENTS.....</b>	<b>459</b>
INTRODUCTION .....	459
APPLICATION OF FTC LAW TO DIETARY SUPPLEMENT ADVERTISING .....	460
<i>Identifying Claims and Interpreting Ad Meaning</i> .....	460
<i>Substantiating Claims</i> .....	463
<i>Other Issues Relating to Dietary Supplement Advertising</i> .....	469
CONCLUSION.....	474
<i>For More Information</i> .....	474
ENDNOTES .....	474

## TABLES

TABLE 1	GLOBAL NUTRITION INDUSTRY SALES & GROWTH.....	53
TABLE 2	SUPPLEMENTS SALES & GROWTH BY REGION .....	54
TABLE 3	US CONSUMER SALES OF FOODS AND SUPPLEMENTS IN \$M.....	54
TABLE 4	VALUE OF THE US CONDITION SPECIFIC SUPPLEMENTS MARKET (\$B) .....	55
TABLE 5	US CONDITION SPECIFIC SUPPLEMENTS MARKET VALUE .....	55
TABLE 6	US CONSUMER SALES OF SPECIALTY SUPPLEMENTS .....	56
TABLE 7	MARKET SHARE OF KEY PRODUCT TYPES IN THE US HEART HEALTH MARKET (RETAIL SALES) .....	56
TABLE 8	RAW MATERIAL SALES OF US HEALTH INGREDIENTS .....	62
TABLE 9	VALUE OF RETAIL, WHOLESALE AND RAW MATERIAL SALES FOR SPECIALTY SUPPLEMENTS IN THE US .....	63
TABLE 10	SALES VALUE GROWTH FOR SPECIALTY SUPPLEMENTS IN THE US (CAGR) .....	63
TABLE 11	US SPECIALTY SUPPLEMENTS VALUE CHAIN % GROWTH YEAR ON YEAR .....	64
TABLE 12	US SPECIALTY SUPPLEMENTS VALUE CHAIN – WHOLESALE AND RAW MATERIAL SALES VALUE AS % OF CONSUMER SALES .....	65
TABLE 13	PER CENT MARK-UP FOR SPECIALTY SUPPLEMENTS RETAILERS AND WHOLESALERS IN THE US .....	66
TABLE 14	SUPPLEMENT SALES BY CATEGORY OF STORE IN THE US .....	68
TABLE 15	COMPARISON OF % OF TOTAL STORES TO % OF SALES FOR US SUPPLEMENTS RETAIL CHANNELS .....	68
TABLE 16	WEEKLY AND <i>PER ANNUM</i> SUPPLEMENT SALES BY STORE TYPE IN THE US.....	68
TABLE 17	2008 US NUTRITION AND SUPPLEMENT SALES BY RETAIL CHANNEL .....	69
TABLE 18	2008 US SUPPLEMENT SALES: RETAIL VERSUS NON-RETAIL.....	71
TABLE 19	2008 US SUPPLEMENT SALES IN NON-RETAIL CHANNELS .....	71
TABLE 20	NCEP’S RECOMMENDED THERAPY FOR LDL-LOWERING .....	72
TABLE 21	PRACTITIONER CHANNEL SUPPLEMENT SALES AND YEAR ON YEAR GROWTH .....	73
TABLE 22	PRACTITIONER CHANNEL SALES IN THE US: TOP 10 COMPANIES .....	74
TABLE 23	TOP 50 US SUPPLEMENT COMPANIES.....	76
TABLE 24	COMPANY 1 NET SALES (PRELIMINARY & UNAUDITED).....	78
TABLE 25	COMPANY 1 PROFIT, PROMOTION AND SG&A AS % OF SALES.....	79
TABLE 26	COMPANY 1 NET INCOME STATEMENT DATA (\$K).....	79
TABLE 27	COMPANY 1 GROSS PROFIT DATA BY SEGMENT (\$K).....	79
TABLE 28	COMPANY 1 ADVERTISING, PROMOTION AND CATALOG DATA BY SEGMENT (\$K).....	80
TABLE 29	COMPANY 1 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (\$K).....	80
TABLE 30	TOP DIRECT-SELLING SUPPLEMENT COMPANIES IN US BY SALES.....	82
TABLE 31	COMPANY 2 RANGE OF DIETARY SUPPLEMENTS.....	84
TABLE 32	COMPANY 3 - CONSOLIDATED STATEMENTS OF OPERATIONS DATA.....	91
TABLE 33	COMPANY 3 - NET SALES IN DOLLARS AND AS A PERCENTAGE OF CONSOLIDATED NET SALES..	91
TABLE 34	COMPANY 3’S PRODUCT PORTFOLIO .....	91
TABLE 35	COMPANY 4 - SUBSIDIARIES .....	98
TABLE 36	STATEMENT OF OPERATIONS DATA (IN ‘000):.....	98
TABLE 37	TOP COMPANIES FOR PRACTITIONER CHANNEL SALES IN US .....	100
TABLE 38	DESIGNS FOR HEALTH - LIST OF STEROL CONTAINING SUPPLEMENTS SOLD.....	101
TABLE 39	DESIGNS FOR HEALTH SUPPLEMENTS - CARDIO VASCULAR HEALTH.....	102
TABLE 40	COMPANY 5 - LIST OF STEROL CONTAINING SUPPLEMENTS SOLD .....	105
TABLE 41	COMPANY 6 - PRODUCTS CONTAINING PLANT STEROLS .....	107
TABLE 42	COMPANY 7 – PRODUCTS AVAILABLE FOR CARDIOVASCULAR SUPPORT.....	109
TABLE 43	COMPANY 8 – PRODUCT CONTAINING STEROL.....	110
TABLE 44	COMPANY 9 – NUMBER OF PRODUCTS SOLD FOR DIFFERENT CARDIOVASCULAR CONDITIONS...	111
TABLE 45	COMPANY 9’S SUPPLEMENTS FOR CHOLESTEROL MANAGEMENT.....	112
TABLE 46	COMPANG 10’S STEROL CONTAINING PRODUCTS .....	114
TABLE 47	COMPANY 10’S SUPPLEMENTS TARGETED AT CARDIOVASCULAR SUPPORT.....	114
TABLE 48	‘POPULAR’ INGREDIENTS USED IN DIETARY SUPPLEMENTS FOR CHOLESTEROL-LOWERING .....	120
TABLE 49	COMMERCIAL SUPPLIERS OF PHYTOSTEROLS, STANOLS AND/OR THEIR ESTERS.....	126
TABLE 50	MAIN HEALTH CLAIMS FOR STEROL / STANOL CONTAINING SUPPLEMENTS .....	128
TABLE 51	EXAMPLE SUPPLEMENT PRODUCTS CONTAINING STEROLS AND/OR STANOLS .....	131
TABLE 52	COMPANY 11’S PRODUCT LABEL DETAILS .....	136
TABLE 53	COMPANY 12’S PRODUCT DETAILS.....	137

TABLE 54	COMPANY 13 PRODUCT .....	139
TABLE 55	COMPANY 14 PRODUCT .....	140
TABLE 56	COMPANY 15 PRODUCT .....	141
TABLE 57	COMPANY 16'S PRODUCT .....	142
TABLE 58	COMPANY 17'S PRODUCT 1.....	143
TABLE 59	COMPANY 17'S PRODUCT 2.....	144
TABLE 60	COMPANY 18'S PRODUCT .....	146
TABLE 61	COMPANY 19'S PRODUCT 1.....	148
TABLE 62	COMPANY 19'S PRODUCT 2.....	150
TABLE 63	COMPANY 20'S PRODUCT .....	151
TABLE 64	COMPANY 21'S PRODUCT 1.....	153
TABLE 65	COMPANY 21'S PRODUCT 2.....	154
TABLE 66	COMPANY 21'S PRODUCT 3.....	155
TABLE 67	COMPANY 21'S PRODUCT 4.....	156
TABLE 68	COMPANY 22'S PRODUCT .....	157
TABLE 69	COMPANY 23'S PRODUCT .....	158
TABLE 70	COMPANY 24'S PRODUCT .....	159
TABLE 71	COMPANY 25'S PRODUCT 1.....	159
TABLE 72	COMPANY 25'S PRODUCT 2.....	161
TABLE 73	COMPANY 25'S PRODUCT 3.....	162
TABLE 74	COMPANY 26'S PRODUCT 1.....	163
TABLE 75	COMPANY 26'S PRODUCT 2.....	164
TABLE 76	COMPANY 26'S PRODUCT 3.....	165
TABLE 77	COMPANY 27'S PRODUCT .....	166
TABLE 78	COMPANY 28'S PRODUCT 1.....	167
TABLE 79	COMPANY 28'S PRODUCT 2.....	169
TABLE 80	COMPANY 29'S PRODUCT .....	170
TABLE 81	COMPANY 30'S PRODUCT .....	172
TABLE 82	COMPANY 31'S PRODUCT .....	172
TABLE 83	COMPANY 32'S PRODUCT .....	174
TABLE 84	COMPANY 33'S PRODUCT .....	175
TABLE 85	COMPANY 34'S PRODUCT 1.....	176
TABLE 86	COMPANY 34'S PRODUCT 2.....	177
TABLE 87	COMPANY 35'S PRODUCT 1.....	178
TABLE 88	COMPANY 35'S PRODUCT 2.....	180
TABLE 89	COMPANY 36'S PRODUCT.....	181
TABLE 90	COMPANY 37'S PRODUCT .....	182
TABLE 91	COMPANY 38'S PRODUCT .....	183
TABLE 92	COMPANY 39'S PRODUCT .....	184
TABLE 93	COMPANY 40'S PRODUCT .....	185
TABLE 94	COMPANY 41'S PRODUCT .....	186
TABLE 95	COMPANY 42'S PRODUCT .....	188
TABLE 96	COMPANY 43'S PRODUCT .....	189
TABLE 97	COMPANY 44'S PRODUCT .....	190
TABLE 98	LICENSED DIETARY SUPPLEMENT PRODUCTS IN CANADA CONTAINING STEROLS.....	192
TABLE 99	COMPANY 45'S PRODUCT INGREDIENTS .....	195
TABLE 100	REQUIREMENTS FOR CANADIAN NATURAL HEALTH PRODUCTS DIRECTORATE LICENCE ....	204
TABLE 101	IMPORT PERMITS - PRODUCTS AND SERVICES .....	216
TABLE 102	SALES AND NET REVENUE FOR COMPANY X (\$K).....	249
TABLE 103	RISK OF AMI IN OVERALL POPULATION .....	309
TABLE 104	CAUSES OF CHD .....	311
TABLE 105	DIAGNOSIS OF CHD .....	316
TABLE 106	TREATMENTS FOR CHD .....	319
TABLE 107	US CLINICAL TRIALS DATABASE.....	321
TABLE 108	US CLINICAL TRIALS DATABASE.....	321
TABLE 109	HEART OUTCOMES PREVENTION EVALUATION-3 (HOPE-3) TRIAL .....	323
TABLE 110	RECOMMENDED CHOLESTEROL GUIDELINES .....	330
TABLE 111	SALES OF ALL DRUGS ON THE US MARKET (\$B) .....	333
TABLE 112	STATIN DRUGS & AVERAGE EFFECTS ON LDL & HDL AT MAXIMUM DAILY DOSE .....	335
TABLE 113	STATIN BRAND NAMES AND PRODUCTION METHOD.....	336

TABLE 114 PATENT POSITION FOR EACH OF THE STATINS IN THE US..... 338

FIGURES

FIGURE 1 US HEART HEALTH SUPPLEMENT MARKET ..... 57
FIGURE 2 SUPPLY CHAIN FLOWCHART - SUPPLEMENTS INDUSTRY ..... 58
FIGURE 3 US NUTRITION INDUSTRY VALUE CHAIN..... 60
FIGURE 4 US NUTRITION INDUSTRY SUPPLY CHAIN ..... 61
FIGURE 5 RAW MATERIAL SALES OF US HEALTH INGREDIENTS ..... 62
FIGURE 6 US SPECIALTY SUPPLEMENTS SALES VALUE ..... 64
FIGURE 7 US SPECIALTY SUPPLEMENTS VALUE CHAIN % GROWTH YEAR ON YEAR ..... 65
FIGURE 8 US SPECIALTY SUPPLEMENTS VALUE CHAIN - WHOLESALE AND RAW MATERIAL SALES VALUE AS % OF CONSUMER SALES ..... 66
FIGURE 9 PER CENT MARK-UP FOR SPECIALTY SUPPLEMENTS RETAILERS..... AND WHOLESALERS ..... 67
FIGURE 10 2008 US NUTRITION AND SUPPLEMENT SALES BY RETAIL CHANNEL ..... 70
FIGURE 11 SUPPLEMENT SALES THROUGH PRACTITIONERS IN THE US (\$M)..... 73
FIGURE 12 CORRECT REGULATORY FRAMEWORK FOR DIETARY SUPPLEMENTS..... 197
FIGURE 13 AGE-ADJUSTED DEATH RATES FOR CHD AS COMPARED TO STROKE, LUNG AND BREAST CANCER FOR FEMALES ..... 307
FIGURE 14 PERCENTAGE BREAKDOWN OF DEATHS FROM CVDS ..... 308
FIGURE 15 ESTIMATED DIRECT/INDIRECT COSTS (\$BILLION) OF MAJOR CVDS/STROKE ..... 308
FIGURE 16 ESTIMATED 10-YEAR CVD RISK IN 50-54-YEAR-OLD ADULTS ACCORDING TO LEVELS OF RISK-FACTORS (FRAMINGHAM HEART STUDY)..... 309
FIGURE 17 PREVALENCE OF CHD BY AGE/SEX. .... 314